Ekf Diagnostics Share Discussion Threads

[srichardson8] 04/2/2021 13:29

The most compelling argument for the further future development of the diagnostic market remains, for me, the latter part of the interview with the boss of Roche on Bloomberg.He has a compelling argument and was himself ic of Roche's diagnostic division for a few years. This link should still work.... https://www.bloomberg.com/quote/ROG:SW

[hatfullofsky] 04/2/2021 11:57

Thank Wan, I've copied your post to the NCYT board

[wan] 04/2/2021 09:31

To add some further perspective regarding Covid-19 testing going into 2021. Recently I reported that some of the large diagnostics players have stated that they see strong sales momentum being maintained during 2021. However, most recently two large players in particular, Thermo-Scientific and PerkinElmer, have implied that they are factoring in a reduction in Covid-19 testing in the second half (but, at least equalling sales in 2020!) due the roll-out of coronavirus vaccines. There are obviously quite a few factors at play here, not least that both Thermo and PerkinElmer are in a state of heightened acquisition mode (and perhaps, given their current and potential targets, they may benefit from making such statements?) The following excerpt from articles further below effectively demonstrates the differences - However, despite the rollout of coronavirus vaccines, Abbott, Hologic and Quidel are all ramping up their manufacturing capabilities in anticipation of another banner year for COVID-19 testing. Abbott CEO Robert Ford said at last month's J.P. Morgan conference that he expects high demand and volume for tests throughout 2021. The following articles provide good coverage beyond the headlines of potentially reduced sales - The persistence of PerkinElmer's COVID-19 tailwind will partly depend on a U.K. testing contract ending in March. The U.K. could extend the contract but as it stands the work is set to cease at the end of next month, leading PerkinElmer to only factor the business into its projections for the first quarter. "Our priority will remain on M&A," PerkinElmer CEO Prahlad Singh said. "I think our appetite is pretty good. And I think we will be acquisitive in 2021." hTTps://www.medtechdive.com/news/perkinelmer-predicts-sharp-falloff-in-covid-19-sales-this-year/594417/ (NB: according to my knowledge, to date PerkinElmer does not utilise PrimeStore MTM) Williamson said demand for COVID-19 tests is anticipated to be strong in the first quarter of 2021 but is expected to decline over successive quarters. Still, he opined "should the pandemic be longer lasting" and the need for coronavirus testing be maintained "then there's sizable upside" particularly in the second half of the year. Although Thermo Fisher envisions testing demand slowing in 2021, the company last month announced it will acquire privately-held molecular diagnostic maker Mesa Biotech for $450 million in cash, with the potential for an additional $100 million upon the completion of certain milestones. The deal is expected to be completed in the first quarter of this year. hTTps://www.medtechdive.com/news/thermo-fisher-q4-fueled-by-covid-19-testing/594277/ "We're assuming that vaccine and therapy revenue is fairly linear in 2021, but testing-related revenue is assumed to be very front-end loaded," Williamson explained, with Q1 levels expected to be similar to Q4 2020 levels. The company's guidance assumes that demand for testing may begin to level off in Q2 and decrease further as the year progresses. "Should the pandemic be longer lasting, and the need for testing maintained, then there's sizeable upside to the $7.1 billion, particularly in the second half of the year," he said. "We're really well positioned to support our customers should demand levels be higher from this initial guidance assumption." hTTps://www.360dx.com/business-news/thermo-fisher-scientific-revenues-rise-54-percent-q4-26-percent-full-year-2020 What's also worth considering, is that if PrimeStore products are increased e.g. ATM is indeed approved, and other transport medias that 'do not' inactivate the virus are in less demand (likely in my view given the increased risks from mutations), it may open new opportunities/partnerships. But overall what's clear from heightened M&A modes, is that the fundamental and dynamic changes in the perception and need for diagnostic testing caused by the pandemic, will be enduring, and subsequently that the growth prospects for the diagnostic industry has materially increased (not just for Covid-19 testing). I am not hoping EKF is a bid target per se (far from it, with strong partnerships being preferred), but more that the core business (including any additional new products) will surely flourish accordingly!

[wan] 04/2/2021 08:01

Cue sequencing too, which has become so important with the need to study mutations on a global basis!

[wan] 04/2/2021 07:58

I note a couple if interesting changes regarding PrimeStore ATM. First, it's notable that the Thermo Scientific site no longer states for "research use only" which implies FDA approval has been received - hTTps://www.fishersci.com/us/en/catalog/search/products?keyword=primestore+atm Second, that the Executive Vice President Global Business Development at Longhorn Vaccines stated the following a few hours ago - "So proud, so humbled. What an award for our company today at the 2021 virtual National Sales Meeting of Fisher Healthcare/Thermo Fisher. It takes Partners, multiple Partners to achieve any sales. Congratulations to all at Thermo Fisher on your sales of our FDA cleared PrimeStore MTM in 2020 (and now into 2021)! Handling and processing safe, inactivated samples is even more important now with the mutations of SARS-CoV-2. Plus the ability to sequence them after qPCR, and then to also safely biobank them for future testing. Thank you to all at Fisher Healthcare/Thermo Fisher and of course your/our customers! There is no award without your belief in and use of PrimeStore MTM, and now also PrimeStore ATM." Which again is another clue that FDA approval for ATM appears to have been received, but not yet officially announced. Not to mention the commitment and sales award for growth from a very large global player.

[74tom] 03/2/2021 09:19

I notice that my HL account is now showing my lock up period Trellus Health shares... can't see any RNS on the spin off but guessing it must be on the way.

[wan] 02/2/2021 07:27

No need to repeat the news most will have already seen regarding the surge testing required in the UK, regardless of symptoms, to try and get to grips with the South African variant (strategic surge testing deployed and required in the future?). But this is not only relevant to the UK, and a global effort is already well underway to not only limit the spread of new variants, but to understand much more about the virus mutations. To summarise, scientists in many countries are working hard to learn more about these variants, and many more studies are needed to understand: How widely these new variants have spread = more PCR testing and sequencing How the disease caused by these new variants differs from the disease caused by other variants that are currently circulating = more PCR testing and sequencing How these variants may affect existing therapies, vaccines, and tests = more testing and sequencing

[wan] 01/2/2021 11:46

Thanks Rivaldo. Apparently nothing has been included by the broker for EKF/Kantaro antibody test revenues. The following starts to put into perspective what the duration for such testing might look like (antibody tests should become an important part of vaccine roll-outs). And not to mention a stronger year for PCR testing than most envisaged, which I believe will endure well beyond 2021 - 1 FEBRUARY 2021 • 11:09AM Coronavirus latest news: UK secures extra 40 million doses of Valneva jab amid plans for repeat vaccines The British government has ordered 40 million further doses of Valneva's Covid vaccine candidate for 2022, the French drugmaker said today. Downing Street said the extra doses would "give the UK future flexibility should we need to revaccinate any of the population". This brings Britain's total orders to 100 million doses, while it retains options for a further 90 million doses between 2023 and 2025, the company said in a statement. hTTps://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-news-covid-vaccine-uk-deaths-lockdown-end/ I have been monitoring UK tender activity for quite some time and the following £1.1B tender for England, Wales, Scotland and Northern Ireland June 2021 - 2023, which includes swab collection and blood sampling requirements also puts some perspective on duration - Published 29 Jan 2021 Description The Office for National Statistics ('ONS') has a requirement to procure Services related to COVID-19. ONS was commissioned in April 2020 to conduct the COVID-19 Infection Survey collecting the data which informs HMG's policies and operational interventions regarding the COVID-19 pandemic. CIS is a repeated cross-sectional household survey with additional serial sampling and longitudinal follow-up which provides an estimate of the proportion and number of people living in private households who would have had COVID-19 in the last week based on trend modelling. The study is led by DHSC and ONS and draws on the world leading scientific expertise of the University of Oxford. CIS is the flagship surveillance study and the key source of COVID-19 infection data, incidence and antibody prevalence in UK communities. We work with key stakeholder partners; PHE, PHS, PHW, the Joint Biosecurity Centre, Ministers, SAGE, and the wider UK Test & Trace programmes to inform required policy and operational interventions. This shall include full survey and fieldwork management, including preparation of training material, recruitment of Study Workers who support participant self-administration of swabs, recruitment of phlebotomists as Study Workers for the collection of venous blood samples and to support participant self-administration of swabs, training and management of the Study Workers, provision of appointment scheduling, supply chain management, venous blood and swab sample management system, end-to-end data flow management, quality assurance, collation of management information, managi... hTTps://bidstats.uk/tenders/2021/W04/743899338

[wan] 01/2/2021 07:40

Food for thought.....Given the new details and rationale, my thoughts extend to the possibility the this new contract might not be a one-off in terms of a PHE contract that enables 'fast-track testing'. Especially now that EKF's new facility and expanded capacity has officially come online.

[rivaldo] 31/1/2021 22:21

Excellent spot wan, thanks. Since N+1 Singer's forecasts only include firm orders regarding COVID-related products, new contract wins such as this £1.2m presumably add nicely to those forecasts for this year.

[wan] 31/1/2021 16:26

Recall that the last Public Health England (PHE) contract awarded to EKF was last October from PHE London for £1.2m hTTps://bidstats.uk/tenders/2020/W43/737214681 I note a new contract award in January 2021, also for £1.2m, this time for PHE Salisbury, but the details and justification are quite different - Published 29 Jan 2021 PHE has awarded a contract to EKF Diagnostics Holding PLC for the provision of Primestore Transport Media in custom tubes to fast track Covid 19 testing. PHE has awarded a contract to EKF Diagnostics Holding PLC for the provision of Primestore Transport Media in custom tubes to fast track Covid 19 testing. Award Detail 1 Ekf Diagnostic Holding (Cardiff) Num offers: 1 Value: £1,200,000 Legal Justification The UK Government must protect the health and wellbeing of UK citizens. The COVID-19 outbreak is a Public Health Emergency of International Concern (PHEIC) as declared by the World Health Organisation on 30 January 2020. The WHO Director General characterised COVID-19 as a pandemic on 11 March 2020. PHE discharges its duties as a Category 1 Responder to emergencies on behalf of the Secretary of State for Health and Social Care within the scope of the Civil Contingencies Act 2004 (CCA 2004). This urgent requirement is in response to the COVID -19 outbreak. A direct award has been made due to extreme urgency under current public procurement regulations using regulation 32(2)(c) to support reduced testing turnaround times which are critical in the current outbreak and increase capacity for Covid 19 testing. hTTps://bidstats.uk/tenders/2021/W04/743899598 "Reduced testing times which are critical" enabled by PrimeStore MTM and recognised not before time in my view! PrimeStore MTM, enabling safe, fast-track testing (and downstream sequencing)!

[mirandaj] 30/1/2021 17:40

EKF Diagnostics reinforcing the fact that 1 in 10 people tested positive for COVID-19 in December: About one in 10 people across the UK tested positive for #COVID19 antibodies in December, roughly double the October figure, data has shown Covid: Positive antibody tests doubled since autumn Some 10% of the UK population is showing signs of recent infection, a doubling since October 28 Jan #COVID19 testing labs can now provide quantitative antibody results too. 1 in 10 in the UK have antibodies. COVID-SeroKlir from Kantaro minimises false positives and negatives, and provides a precise result #CovidTesting https://ekfdiagnostics.com/COVID-SeroKlir.htm https://mobile.twitter.com/EKFdiagnostics

[sharw] 29/1/2021 19:06

rivaldo - you are making me nostalgic! The first house I bought was in Llandough but it, together with its trading estate is not in Cardiff, it is in the Vale of Glamorgan as is adjacent Penarth. That means it is less than 2 miles from EKF in Stanwell Rd. EKF's press release refers to "Penarth, Cardiff", which would probably ruffle a few local feathers.

[wan] 29/1/2021 08:42

Another one of the big diagnostic guns firing both barrels - Danaher Q4 Revenues Up 39 Percent Jan 28, 2021 NEW YORK – Danaher reported on Thursday a 39 percent year-over-year increase in total sales for the fourth quarter, beating the consensus Wall Street estimate. Blair said Danaher's underlying base business increased approximately 4 percent in the fourth quarter. He added that Danaher is expanding its production capacity at subsidiaries Cepheid, Cytiva, and Pall Biotech to "support increasing demand for COVID-related testing and treatment." Meanwhile, Cepheid, part of the Diagnostics segment, saw more than 100 percent core growth and passed $2 billion in annual revenue, one year after hitting the $1 billion mark, Blair said. During the quarter, Cepheid shipped approximately 9 million test cartridges, and Blair said the firm expects to ship 9 million during each quarter this year. Approximately 60 percent of the respiratory tests shipped were for SARS-CoV-2 only, while 40 percent were the 4-in-1 test for SARS-CoV-2, influenza A/B, and respiratory syncytial virus, he added. In Asia, there was a preference for the SARS-CoV-2-only test because the flu isn't as prevalent there, but in Europe there has been increasing adoption of the 4-in-1 test, although it's been staggered country by country, Blair said. Cepheid also placed "a record number" of new GeneXpert systems, increasing its installed base 35 percent in 2020 to more than 30,000 instruments globally. Blair said the company has been thoughtful in placing those instruments, so they will "find great utilization" in the long term once COVID-19 testing demand has decreased. The company ended the year with $6.04 billion in cash and cash equivalents. In a statement, Blair said "2020 was also a transformative year for Danaher with the addition of Cytiva — the largest acquisition in our company's history and one that has strengthened our position as a global science and technology leader." Cytiva generated more than $4 billion in revenue and 25 percent revenue growth in 2020, Blair said on the call. He also noted a "record bioprocessing demand," with Cytiva and Pall's combined order growth up more than 50 percent in the quarter. The 2021 revenue opportunity associated with COVID-19 vaccines and therapeutics in the bioprocessing business is expected to be $1.3 billion, Blair said. Cytiva's strong performance has helped offer Danaher "more degrees of freedom" to make deals, but Blair said the firm will likely focus on smaller to midsized mergers and acquisitions for the time being. For the first quarter of 2021, Danaher forecast core revenue growth including Cytiva will be in the mid to high teens range. Blair added the firm expects mid-single-digit growth in non-COVID-19 related businesses. For full-year 2021, Danaher expects core revenue growth in the low double digits. Blair said the second half of the year would have tougher prior-year comparisons due to the significant growth in the second half of 2020. He also said the firm expects non-COVID-19-related businesses to see mid- to high single-digit growth. Full story - hTTps://www.360dx.com/business-news/danaher-q4-revenues-39-percent Point of interest, PrimeStore® MTM has been validated on wide range of high throughput platforms, including Cepheid.

[wan] 29/1/2021 07:57

An insightful read - 4 key trends for medtech in 2021 COVID-19 challenges, and opportunities, will continue to impact companies this year. AUTHOR Greg Slabodkin PUBLISHED Jan. 29, 2021 Another banner year for COVID-19 testing Demand for COVID-19 testing will continue to accelerate over the next year, with volumes remaining high until vaccines are widely distributed, according to Moody's. Despite the rollout of coronavirus vaccines, Abbott, Hologic and Quidel are ramping up their manufacturing capabilities in anticipation of another banner year for COVID-19 testing. CEOs from the diagnostic makers laid out their coronavirus test plans earlier this month at J.P. Morgan. "Everybody thought as soon as vaccines came, testing is going to go away. I think everybody is now seeing the realities of rolling out vaccines, of distribution chains. There is so much more complexity," MacMillan said. "This market, we believe, continues to grow and continues to be strong. And while it will certainly come down at some point, we believe it's going to be stronger for longer." Tuck-in acquisitions poised to take off While M&A slowed last year due to the coronavirus pandemic, a report from consultancy EY predicts medtech dealmaking to jump in 2021 as companies are armed with a record high of roughly $500 billion in financial firepower. So far this year, the industry has seen a flurry of activity. While some companies will look for tuck-in acquisitions, a handful of deals over $1 billion should be expected, according to John Babbitt, EY's MedTech leader for the Americas. In addition, EY sees several subsectors as top targets in 2021 for M&A activity including diagnostics, digital health, and remote patient monitoring. Digital, remote tech adoption to grow The company has “leveraged COVID” to accelerate its digital investments and capabilities in such focus areas as clinical trials, customer engagement, mobile solutions, medical education and remote case support, Mahoney said. Boston Scientific’s initiatives include remote case support and virtual reality solutions, remote monitoring of clinical trials, as well as teleproctoring and virtual medical education. “We see these platforms as a key catalyst for growth and structural and cost savings opportunities over time, and continue to expand our footprints and these digital capabilities,” Mahoney added. Full article and a worthy read - hTTps://www.medtechdive.com/news/4-key-trends-for-medtech-in-2021/593856/

[rivaldo] 28/1/2021 14:35

NIce feature today on the expansion in Cardiff: Https://www.insidermedia.com/news/wales/ekf-expands-into-second-manufacturing-facility-in-cardiff "EKF expands into second manufacturing facility in Cardiff 28 Jan 2021 EKF Diagnostics has expanded its production with the introduction of a new manufacturing facility in Cardiff. The expansion is to help the listed business meet demand for PrimeStore MTM, a key component of the Covid-19 testing process. PrimeStore MTM allows Covid-19 samples from swabs to be rapidly inactivated in the collection tube, enabling safe transportation and avoiding contamination while preserving RNA for accurate analysis without the need for refrigeration. The new facility is more than 600 sq. metres, representing a 100 per cent increase in manufacturing space. Up to 36,000 PrimeStore MTM tubes will be produced at Llandough every day, adding to EKF’s existing manufacturing onsite at Penarth and at its three other facilities in Texas and Indiana in the US, and Barleben, Germany. EKF engaged only local contractors during the fitting out process and now finished, the new facility at Llandough will provide work for up to 40 staff, operating three tube filling pump lines and three rooms for sample kit assembly. Already EKF has created over 30 new jobs on the production line and in quality assurance, customer services, purchasing, operations and logistics to meet the demand for PrimeStore MTM. EKF expects to employ more staff as it settles into the new facility. EKF’s continued growth, has created opportunities for many other new employees from a diverse range of Covid-19 impacted industries. The new manufacturing facility will also become a distribution hub for EKF’s latest portfolio addition, Covid-SeroKlir which is an antibody test developed by Kantaro Biosciences based on technology from Mount Sinai Health System in New York. EKF chief executive Julian Baines said: "We are proud to be bucking the current employment trend in Wales by taking this strategic decision to increase the size of our manufacturing facilities in Cardiff. We could have stayed in our previous manufacturing space but by moving into larger facilities we have room for growth and can ensure our growing staff numbers can operate in a safe and secure environment." He added: "Although Covid-19 vaccines are being rolled out, we are still experiencing strong demand from both public and private sector customers for PrimeStore MTM. "We are also about to launch our new Covid-19 antibody testing kit which we believe will also be of interest to labs, hospitals and businesses who want to identify which members of staff have antibodies. Those with a high antibody count will have strong resistance to the virus and with regular monitoring can return to the workplace."

[wan] 28/1/2021 09:45

An interesting development (previously delayed) within the NHS, with savings also being an important part the underlying rationale - MedTech Funding Mandate policy 2021/22 Guidance for NHS commissioners and providers of NHS-funded care Foreword I am delighted to be launching the MedTech Funding Mandate policy to support commissioners and providers to use clinically effective and cost-saving medical devices, diagnostics and digital technologies that will improve patient outcomes. This policy will benefit patients by enabling faster and wider sustainable adoption of proven and affordable innovations, a commitment in The NHS Long Term Plan. COVID-19 has impacted all of our lives and been the greatest challenge to the NHS in generations. The response to COVID-19 delayed the previous launch of the MedTech Funding Mandate, but the response has also taught us that we now can’t lose the opportunity to embed positive changes and we should continue to build on our collaborative working and strength our partnerships across the health system. The MedTech Funding Mandate underscores the importance of companies working with NICE to put their technologies through the appropriate assessments. NHS England and NHS Improvement will consider technologies proven to be clinically and cost-effective for inclusion in the future updates of the policy. We look forward to working with you to implement the MedTech Funding Mandate to make sure the best medical technologies get to patients faster. Criteria for inclusion in the MedTech Funding Mandate 2021/22 11. We reviewed all NICE medical technologies guidance (MTGs) and NICE diagnostics guidance (DGs) published by 30 June 2020 to identify devices, diagnostics or digital products that: i) are effective: demonstrated through a positive NICE MTG or DG; 5 ii) deliver material savings to the NHS: the benefits of the innovation are over £1 million over five years for the population of England; iii) are cost-saving in-year: NICE modelling demonstrates a net saving in the first 12 months of implementing the technology; iv) are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years. 6 12. To ensure that the adoption of this policy does not create undue burden on providers and commissioners, it is being launched in 2021/22 with a small number of products that meet the criteria above, and a fifth criterion that the products were previously supported through the ITT/ITP programmes. 7 hTTps://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2021/01/mtfm-policy-guidance-jan-2021.pdf We’re bringing together industry, government, regulators, patients and the NHS to remove barriers and accelerate the introduction of ground-breaking new treatments and diagnostics which can transform care. The AAC supports all types of innovations: medicines, diagnostics, devices, digital products, pathway changes and new workforce models. hTTps://www.england.nhs.uk/aac/ Those up to speed will already be aware of the Trellus Health business rationale, which appears to dovetail quite well with what the NHS and other health services are looking for. Not to mention what Point of care tests offer in terms of patient benefits and earlier interventions and savings etc. The NHS has never been a main pillar of revenue for EKF's core business, far from it, however, I do recall EKF stating that there were encouraging signs of greater adoption within the NHS.

[wan] 28/1/2021 07:58

The diagnostic big guns are starting to report their earnings. To summarise, they are reporting very robust Covid related testing growth and related earnings, outstripping analysts expectations. Earnings momentum is expected to continue through 21 with higher confidence in the normalization of their underlying businesses, including growth in some areas such as diabetes. Excerpts from Abbott- 110% jump in diagnostics sales compared to the prior year was driven by strong demand for its rapid antigen and PCR-based coronavirus tests. CEO Robert Ford told investors on Wednesday's earnings call that he sees "sustainability" in 2021 for testing despite the rollout of COVID-19 vaccines. hTTps://www.medtechdive.com/news/abbot-q4-beats-estimates-fueled-by-COVID19-testing/594036/ Abbott said it anticipates full-year 2021 earnings per share from continuing operations of at least $3.74. Adjusted EPS from continuing operations for 2021 is expected to be at least $5.00. Ford said he expects COVID-19 testing to continue to be a big driver of Abbott's revenue even as vaccines continue to roll out. "I don't think we've even seen testing demand peak yet," he said. On the mergers and acquisitions side, Ford said the company is always looking for opportunities but continued that any deals in 2021 would likely "be tuck-in in nature" to augment some of the firm's existing portfolios. hTTps://www.360dx.com/business-news/abbott-q4-diagnostics-revenues-111-percent-fy20-revenues-9-percent Hologic excerpts - Hologic Fiscal Q1 Revenues Rise 89 Percent as Dx Testing Demand Surges Jan 27, 2021 NEW YORK – Hologic reported after the close of the market on Wednesday that revenues for its first quarter of fiscal year 2021 surged 89 percent year over year, driven by sales of its diagnostic testing products for SARS-CoV-2. "Hologic had a strong start to fiscal 2021 across all our businesses and major geographies," Steve MacMillan, the company’s chairman, president, and CEO, said in a statement. "Our Diagnostics division continued to deliver incredible performance by making a massive impact against COVID-19." hTTps://www.360dx.com/business-news/hologic-fiscal-q1-revenues-rise-89-percent-dx-testing-demand-surges

[tongosti] 28/1/2021 07:04

You wouldn't know it pal (as my approach is fundamentally different from yours) but I look at every single piece of valid info before I step in. If you really think about it, one is in charge of protecting own capital only in this game, with the market being in charge of returns. In other words, being obsessed with managing risk (and minimising the cost of one's mistakes) is hardly a trait of a "bag of nerves" personality type but rather something entirely different. Like I said, my approach is entirely different to yours.

[boadicea] 27/1/2021 21:40

tong - Sometimes it helps just to have a look at the market background. You must be a bag of nerves!

[tongosti] 27/1/2021 15:54

Never give the tape the benefit of the doubt. Nobody in this universe (this doesn't apply to a few space geniuses floating around here:) knows the difference between a temp dip and the start of a major crash. Covered my long for a ... gigantic 3% loss. Happy to stand aside until another signal comes along.

[speedsgh] 26/1/2021 17:12

Fund managers' favourite UK smaller companies - HTTPS://www.investorschronicle.co.uk/tips-ideas/2020/11/18/fund-managers-favourite-uk-smaller-companies-shares/ EKF is in joint second place alongside SDL, behind Future in top spot.

[wan] 25/1/2021 16:23

Just to put some more context into my previous comment regarding the attributes of PrimeStore MTM offering users a safe, and more efficient sample collection process, via the elimination of cold chain logistics, which in turn reduce costs - From Thermo Fisher Scientific - Description *PrimeStore™ MTM is the only FDA Cleared (cleared in 2018) Molecular Transport *Medium for respiratory samples suspected of harboring influenza or TB. *Considered by US FDA as a primary sample collection device for SARS-CoV-2. *PrimeStore™ collected samples enable safe handling for both point of care and in the laboratory--since the entire sample in inactivated/killed including SARS-CoV-2 and more resilient microbes like gram positives, etc. *Once a swab or biofluid is added to PrimeStore™ the user has a “snapshot” in time for that sample. *The DNA, and more importantly the labile RNA is preserved/stabilized. *Groups all over the United States, Europe, and Africa/Asia use PrimeStore™ to move and transport samples across borders using NORMAL FedEX and UPS shipping. - Since the pathogens collected are eliminated, the samples can be shipped using routine boxing/shipping methods. - Samples in PrimeStore™ can be shipped with NO COLD CHAIN, no wet or dry ice. *Samples do not have to be pre-processed in BLS-III or even BLS-II safety levels. *Safe or normal technician testing. *The collected sample in PrimeStore™ can be used/re-used several times for additional testing. *Many Labs use the first sampling for detection by qPCR and the second for NGS or gene sequencing. *PrimeStore™ MTM was designed to be compatible with all Qiagen-based extraction systems (bench top and high throughput liquid handling systems). It works with the Thermo Scientific MagMax, Roche MAGNAPURE or almost all DNA/RNA liquid handling extraction systems. *The medium if in cryotubes can be frozen at ultra-low for biobanking or simply stored in the refrigerator (since the medium is safely preserving the collected sample). hTTps://www.fishersci.com/shop/products/molecular-transport-media-2/p-8986001

[tongosti] 25/1/2021 12:41

Following from my previous post this is a good market action against the larger backdrop of weaker markets. Not out of the woods yet for me to raise my stop above entry but getting close. Let's see what Mr Market will make of it all this week.